Latest Pharma and Biotech News
Pharmaceutical
4 April 2025 A planned autumn review of the UK’s 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) will be brought forward to report back in June, it has been announced.
Today's issue
Refine Search
Biotechnology
Antibody drug conjugates (ADCs) are currently in vogue with investors and big pharma, as a rapidly emerging class of therapeutic agents that combine the target specificity of a monoclonal antibody with the lethality of cytotoxic cellular poison. 10 April 2024
Biotechnology
Swiss ophthalmology firm Oculis Holding today announced the appointment of Dr Snehal Shah, executive leader with over two decades of research and development (R&D) and regulatory experience, to the role of president of R&D. 10 April 2024
Biotechnology
Swiss inflammatory diseases specialist MoonLake Immunotherapeutics has teamed up with US tech platform company Komodo Health. 10 April 2024
Pharmaceutical
Cell programming specialist Ginkgo Bioworks today announced the expansion of its strategic partnership with Denmark’s Novo Nordisk under a framework agreement that initially is contemplated to run over five years. 10 April 2024
Biotechnology
A new biotech has launched in the thriving biotech hub around Boston, USA. 10 April 2024
Biotechnology
There has been an uptick in licensing agreements for drugs incorporating clustered regularly interspaced short palindromic repeats (CRISPR)-based technology over the past five years, notes GlobalData. 10 April 2024
Pharmaceutical
Japan-based Teijin Group’s healthcare business, Teijin Pharma, has entered into an exclusive global licensing agreement with French drugmaker Bioprojet Pharma. 10 April 2024
Pharmaceutical
British specialty medicines firm Essential Pharma has announced the completion of the acquisition of the entire issued share capital of fellow UK-based Renaissance Pharma. 10 April 2024
Biotechnology
Swiss drugmaker Novartis has revealed fresh plans to slim down its workforce, with a further 680 US and Swiss positions
to be cut. 10 April 2024
Generics
For the last three decades, the availability of cost-effective generic medicines has driven increased access to life-saving treatments for millions of patients in Europe. 10 April 2024
Pharmaceutical
The segment of public procurement of medicines in Russia is facing a serious crisis due to the ever-growing number of failed tenders, caused by a low interest of suppliers and drugmakers for them, The Pharma Letter’s local correspondent reports. 10 April 2024
Pharmaceutical
Research suggests there will likely be strong uptake for the first USA-approved therapy for metabolic dysfunction-associated steatohepatitis (MASH). 9 April 2024
Pharmaceutical
Nearly eight years after the UK voted to leave the European Union (EU), the government is still delaying on introducing certain new rules that impact the life sciences industry. 9 April 2024
Biotechnology
Asklepios BioPharmaceutical, the wholly-owned but independently operated subsidiary of Bayer, has appointed a new chief scientific officer. 9 April 2024
Biotechnology
The biopharmaceutical industry is currently facing pressure from expiring patents, which are expected to result in a $100 billion headwind for the industry over the next five years. 9 April 2024
Generics
The Russian drugmaker Geropharm says it plans to launch a generic copy of Danish drugmaker Novo Nordisk’s Wegovy (semaglutide) for the treatment of obesity, reports The Pharma Letter’s local correspondent. 9 April 2024
Biotechnology
Seaport Therapeutics has become the latest founded entity to be created by PureTech Health, the Boston-based biotech behind Karuna Therapeutics, which was recently acquired by Bristol Myers Squibb for $14 billion. 9 April 2024
Pharmaceutical
Results from the Phase III clinical trial MONeT (RSV IMmunizatiON Study for AdulTs at Higher Risk of Severe Illness), evaluating a single dose of Abrysvo versus placebo in adults 18 to 59 years of age at risk of developing severe respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD), were released today by Pfizer. 9 April 2024
Pharmaceutical
Sino Biopharmaceutical revealed it has entered into a strategic partnership with Boehringer Ingelheim to bring the German family-owned company’s innovative cancer therapies to the market in mainland China. 9 April 2024
Pharmaceutical
The US regulator has once more rebuffed efforts on the part of Supernus Pharmaceuticals to register its Parkinson’s disease candidate SPN-830. 9 April 2024
All news
Pharmaceutical
al rule on April 4, that modernizes and improves Medicare Advantage (MA), Medicare Prescription Drug Benefit (Part D), Medicare cost plan, and Programs of All-Inclusive Care for the Elderly (PACE) programs.
New Medicare proposals will not cover obesity drugs
April 4, 2025 5 April 2025
Pharmaceutical
A planned autumn review of the UK’s 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) will be brought forward to report back in June, it has been announced. 4 April 2025
Pharmaceutical
US private equity firm Vance Street Capital has expanded its life sciences manufacturing platform with the acquisition of Irish contract manufacturer Zenith Adhesive Components, adding further technical capabilities and boosting regional reach. 4 April 2025
Pharmaceutical
Swedish biotech OncoZenge has expanded its regulatory team as it prepares for a Phase III trial of BupiZenge (bupivacaine), a non-opioid treatment for oral pain caused by cancer therapies. 4 April 2025
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences today announced the appointment of Sanjay Keswani to the company's executive management team as chief medical officer (CMO) effective June 2, 2025. 4 April 2025
Biotechnology
Dark Blue Therapeutics, a UK discovery and development biotech developing precision oncology medicines, has announced the appointment of Edwin Moses as chairman. 4 April 2025
Biotechnology
The US Food and Drug Administration (FDA) has approved Uplizna (inebilizumab-cdon) as the first and only treatment for adults living with immunoglobulin G4-related disease (IgG4-RD), the drug’s developer, Amgen announced yesterday. 4 April 2025
Biotechnology
US biotech MoonLake Immunotherapeutics has entered into an agreement with Hercules Capital for up to $500 million in non-dilutive capital, of which $75 million drawn down at close and additional tranches will become available upon achievement of certain pre-specified milestones that are aligned with MoonLake’s strategy and funding needs. 4 April 2025
Biotechnology
Struggling US genomic medicines company Sangamo Therapeutics has been offered a lifeline via a licensing deal with pharma major Eli Lilly, sending its share up 24% to $0.77. 4 April 2025
Biosimilars
An Expert View from Dr Elena Wolff-Holz, global head of clinical development at Biocon Biologics, the biosimilar subsidiary of Biocon. 4 April 2025
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Wainzua (eplontersen) to treat adults with polyneuropathy associated with hereditary transthyretin amyloidosis (ATTRv), which is a rare progressive condition that runs in families caused by a protein called transthyretin (TTR). 4 April 2025
Pharmaceutical
US biotech Aldeyra Therapeutics has received a Complete Response Letter from the US Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of its dry eye disease candidate reproxalap. 4 April 2025
Biotechnology
Swiss pharma giant Roche’s Genentech subsidiary has presented new data at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, Austria. 4 April 2025
Biotechnology
A new report from GlobalData has raised concerns over the effectiveness of mpox vaccines for people living with HIV. 4 April 2025
Biotechnology
UK pharma major AstraZeneca today reported extended approvals in Europe for two of its cancer drugs: Imfinzi (durvalumab) and Enhertu (trastuzumab deruxtecan). 4 April 2025
Biotechnology
US biotech Novavax is still waiting on a decision from the Food and Drug Administration over full approval of its protein-based COVID-19 vaccine, despite the agency having set an April 1 target date to complete its review. 4 April 2025
Biotechnology
US regenerative cell therapy specialist Neurona Therapeutics has announced the successful completion of an upsized and oversubscribed $102 million financing. 4 April 2025
Pharmaceutical
US pharma major Eli Lilly’s brand value has surged by 108% since entering the weight loss market in 2023, according to a new report from Brand Finance. 3 April 2025
Biotechnology
US biotech BioMarin Pharmaceutical yesterday revealed that the Phase III PEGASUS trial evaluating Palynziq (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically-significant lowering in blood phenylalanine( Phe) levels in adolescents aged 12-17 with phenylketonuria (PKU) compared to diet alone. 3 April 2025
Biotechnology
Sino-American biotech BeiGene today revealed it intends to discontinue its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer. 3 April 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze